MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

Search

Recursion Pharmaceuticals Inc

Closed

SectorHealthcare

4.81 3.22

Overview

Share price change

24h

Current

Min

4.72

Max

4.9399999999999995

Key metrics

By Trading Economics

Income

9.6M

-162M

Sales

-14M

5.2M

Profit margin

-3,135.324

Employees

800

EBITDA

6.4M

-141M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+64.89% upside

Dividends

By Dow Jones

Next Earnings

27 Feb 2026

Market Stats

By TradingEconomics

Market Cap

-97M

2.3B

Previous open

1.59

Previous close

4.81

News Sentiment

By Acuity

50%

50%

173 / 370 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

12 Jan 2026, 23:54 UTC

Market Talk

CBA Could Underperform Again in 2026 -- Market Talk

12 Jan 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12 Jan 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

12 Jan 2026, 23:43 UTC

Market Talk

Gold Edges Lower on Likely Technical Correction -- Market Talk

12 Jan 2026, 23:18 UTC

Acquisitions, Mergers, Takeovers

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

12 Jan 2026, 21:56 UTC

Market Talk

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

12 Jan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 Jan 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

12 Jan 2026, 21:50 UTC

Market Talk
Earnings

Auto & Transport Roundup: Market Talk

12 Jan 2026, 21:18 UTC

Market Talk

Global Equities Roundup: Market Talk

12 Jan 2026, 21:18 UTC

Market Talk

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

12 Jan 2026, 20:54 UTC

Earnings

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

12 Jan 2026, 20:48 UTC

Market Talk

Oil Futures Settle Higher in Choppy Trade -- Market Talk

12 Jan 2026, 20:33 UTC

Market Talk

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

12 Jan 2026, 20:18 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

12 Jan 2026, 20:18 UTC

Acquisitions, Mergers, Takeovers

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

12 Jan 2026, 19:39 UTC

Market Talk

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

12 Jan 2026, 19:36 UTC

Market Talk

Gold and Silver Set New Records on Fed Probe -- Market Talk

12 Jan 2026, 19:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12 Jan 2026, 19:33 UTC

Market Talk

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

12 Jan 2026, 19:24 UTC

Acquisitions, Mergers, Takeovers

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12 Jan 2026, 19:22 UTC

Acquisitions, Mergers, Takeovers

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

12 Jan 2026, 18:21 UTC

Acquisitions, Mergers, Takeovers

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

12 Jan 2026, 18:20 UTC

Acquisitions, Mergers, Takeovers

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

12 Jan 2026, 18:19 UTC

Market Talk

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

12 Jan 2026, 18:16 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

12 Jan 2026, 18:09 UTC

Market Talk

Global Equities Roundup: Market Talk

12 Jan 2026, 18:09 UTC

Market Talk

Baidu's Outlook Bodes Well For Shares -- Market Talk

12 Jan 2026, 18:01 UTC

Acquisitions, Mergers, Takeovers

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

12 Jan 2026, 18:00 UTC

Market Talk

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Peer Comparison

Price change

Recursion Pharmaceuticals Inc Forecast

Price Target

By TipRanks

64.89% upside

12 Months Forecast

Average 7.75 USD  64.89%

High 11 USD

Low 5 USD

Based on 6 Wall Street analysts offering 12 month price targets forRecursion Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

6 ratings

2

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

4.15 / 4.75Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

173 / 370 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
help-icon Live chat